Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^* MPM BioVentures 2014, L.P.	2. Issuer Name and Ticker or Trading Symbol iTeos Therapeutics, Inc. [ ITOS ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director __X__ 10% Owner _____ Officer (give title below) _____ Other (specify below)
(Last) (First) (Middle) C/O MPM CAPITAL, 450 KENDALL STREET	3. Date of Earliest Transaction (MM/DD/YYYY) 10/15/2021
(Street) CAMBRIDGE, MA 02142 (City) (State) (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) ___ Form filed by One Reporting Person _ X _ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	10/15/2021		S⁽¹⁾		8893 ⁽²⁾	D	$27.53 ⁽³⁾	3143197	I	See Footnote ⁽⁴⁾
Common Stock	10/15/2021		S⁽¹⁾		2039 ⁽⁵⁾	D	$28.01 ⁽⁶⁾	3141158	I	See Footnote ⁽⁷⁾
Common Stock	10/18/2021		S⁽¹⁾		6167 ⁽⁸⁾	D	$27.14 ⁽⁹⁾	3134991	I	See Footnote ⁽¹⁰⁾

*Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)*
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)			11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:
(1)	Transaction effected pursuant to a plan established pursuant to Rule 10b5-1.
(2)	The shares were sold as follows: 5,298 by MPM BioVentures 2014, L.P. ("BV 2014"), 182 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 3,347 by MPM BioVentures 2018, L.P. ("BV 2018") and 66 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV 2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV 2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV 2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evnin and Foley are managing directors of BV 2014 LLC and BV 2018 LLC.
(3)	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.97 to $27.955 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
(4)	The shares are held as follows: 1,776,194 by BV 2014, 107,713 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 61,134 by AM BV2014, 1,121,805 by BV 2018, 54,213 by MPM BioVentures 2018(B), L.P. ("BV 2018(B)") and 22,138 by AM BV2018. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.
(5)	The shares were sold as follows: 1,215 by BV 2014, 42 by AM BV2014, 767 by BV 2018 and 15 by AM BV2018.
(6)	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.97 to $28.07 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
(7)	The shares are held as follows: 1,774,979 by BV 2014, 107,713 by BV 2014(B), 61,092 by AM BV2014, 1,121,038 by BV 2018, 54,213 by BV 2018(B) and 22,123 by AM BV2018. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any.
(8)	The shares were sold as follows: 3,676 by BV 2014, 125 by AM BV2014, 2,321 by BV 2018 and 45 by AM BV2018.
(9)	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.96 to $27.94 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
(10)	The shares are held as follows: 1,771,303 by BV 2014, 107,713 by BV 2014(B), 60,967 by AM BV2014, 1,118,717 by BV 2018, 54,213 by BV 2018(B) and 22,078 by AM BV2018. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.

Remarks:
See Form 4 for MPM BioVentures 2018, L.P for additional members of this joint filing.

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
MPM BioVentures 2014, L.P. C/O MPM CAPITAL 450 KENDALL STREET CAMBRIDGE, MA 02142		X
EVNIN LUKE C/O MPM CAPITAL 450 KENDALL STREET CAMBRIDGE, MA 02142		X
Foley Todd C/O MPM CAPITAL 450 KENDALL STREET CAMBRIDGE, MA 02142		X
MPM BioVentures 2014 (B), L.P. C/O MPM CAPITAL 450 KENDALL STREET CAMBRIDGE, MA 02142		X
MPM Asset Management Investors BV2014 LLC C/O MPM CAPITAL 450 KENDALL STREET CAMBRIDGE, MA 02142		X
MPM BioVentures 2014 LLC C/O MPM CAPITAL 450 KENDALL STREET CAMBRIDGE, MA 02142		X
MPM BioVentures 2014 GP LLC C/O MPM CAPITAL 450 KENDALL STREET CAMBRIDGE, MA 02142		X
MPM BIOVENTURES 2018 (B), L.P. C/O MPM CAPITAL 450 KENDALL STREET CAMBRIDGE, MA 02142		X
MPM ASSET MANAGEMENT INVESTORS BV2018 LLC C/O MPM CAPITAL 450 KENDALL STREET CAMBRIDGE, MA 02142		X

Signatures
/s/ Ansbert Gadicke, managing director of MPM BioVentures 2014 LLC, the managing member of MPM BioVentures 2014 GP LLC, the general partner of MPM BioVentures 2014, L.P.		10/18/2021
^**Signature of Reporting Person		Date
/s/ Luke Evnin		10/18/2021
^**Signature of Reporting Person		Date
/s/ Todd Foley		10/18/2021
^**Signature of Reporting Person		Date
/s/ Ansbert Gadicke, managing director of MPM BioVentures 2014 LLC, the managing member of MPM BioVentures 2014 GP LLC, the general partner of MPM BioVentures 2014 (B), L.P.		10/18/2021
^**Signature of Reporting Person		Date
/s/ Ansbert Gadicke, managing director of MPM BioVentures 2014 LLC, the manager of MPM Asset Management Investors BV2014 LLC		10/18/2021
^**Signature of Reporting Person		Date
/s/ Ansbert Gadicke, managing director of MPM BioVentures 2014 LLC		10/18/2021
^**Signature of Reporting Person		Date
/s/ Ansbert Gadicke, managing director of MPM BioVentures 2014 LLC, the managing member of MPM BioVentures 2014 GP LLC		10/18/2021
^**Signature of Reporting Person		Date
/s/ Ansbert Gadicke, managing director of MPM BioVentures 2018 LLC, the managing member of MPM BioVentures 2018 GP LLC, the general partner of MPM BioVentures 2018 (B), L.P.		10/18/2021
^**Signature of Reporting Person		Date
/s/ Ansbert Gadicke, managing director of MPM BioVentures 2018 LLC, the manager of MPM Asset Management Investors BV2018 LLC		10/18/2021
^**Signature of Reporting Person		Date